 SAN DIEGO, May 14, 2021 PRNewswire -- Kintara Therapeutics, Inc. Nasdaq: KTRA Kintara or the Company, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2021 and provided a corporate update. Fiscal Third Quarter Highlights and Recent Developments Commenced patient recruitment of Kintaras VAL-083 arm of the glioblastoma multiforme GBM AGILE registrational study sponsored by the Global Coalition for Adaptive Research GCAR. 